RESEARCH ON THE CLINICAL AND PARACLINICAL CHARACTERISTICS AND RESULTS OF DAPAGLIFLOZIN COMBINATION REGIMEN TREATMENT IN PATIENTS WITH CHRONIC HEART FAILURE MILDLY-REDUCED EJECTION FRACTION AT KIEN GIANG GENERAL HOSPITAL IN 2023–2024
Main Article Content
Abstract
Background: Heart failure with mildly reduced ejection fraction is defined as a left ventricular ejection fraction of 41–49%. Currently, the incidence of heart failure with mildly reduced ejection fraction increases with age, so early aggressive treatment with many groups of drugs as recommended helps improves the rate of hospital readmission and death. Objectives: To analyze the results of treatment with a regimen containing the drug dapagliflozin individuals with heart failure with mildly-reduced ejection fraction. Materials and methods: A cross-sectional descriptive study with intervention without control group on 41 patients with heart failure with mildly reduced ejection fraction at Kien Giang General Hospital. Results: The mean age of the participants was 65.7 ± 13.3. Males include a larger percentage than females (57.2% vs 46.3%); heart failure in the family history (12.2%); number of years affected by heart failure 4.8 plus or minus 2.2. NT-proBNP dramatically dropped to 145.3 ± 38.2 pg/mL after improving to 1046.1 ± 2941.9 pg/mL. After 3 months of followup, the readmission rate was 12.2% (month 1), and 17.1% (during 3 months). Conclusion: A combination regimen with dapagliflozin in the treatment of heart failure with a mildly reduced ejection fraction is effective in improving clinical symptoms, reducing NT-proBNP levels, and reducing hospital readmission rates within 3 months.
Article Details
Keywords
Heart failure with mildly reduced ejection fraction (HFmrEF), dapagliflozin
References
2. McDonagh TA., Metra M. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021. 42(36), 3599-3726, DOI: 10.1093/eurheartj/ehab368.
3. Zelniker TA., Wiviott SD., Raz I., Im K., Goodrich EL., Bonaca MP., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019. 393(10166), 31-39, doi: 10.1016/S0140-6736(18)32590-X.
4. Vergaro, Giuseppe, Ghionzoli, Nicolò, Innocenti, et al. Noncardiac versus cardiac mortality in heart failure with preserved, midrange, and reduced ejection fraction. Journal of the American Heart Association. 2019. 8(20), ee013441, DOI: https://doi.org/10.1161/JAHA.119.013441.
5. Nguyễn Đức Khánh. Vai trò tiên lượng ngắn hạn của sST2 ở bệnh nhân suy tim mạn nhập viện. Y Học thành phố Hồ Chí Minh. 2022. 26 (1), 76-83, DOI: 10.51226/johcm.2022.1.76-83.
6. McMurray JJV., Solomon SD. et al. Dapagliflozin in Patients with Heart Failure and Reduced. The new england journal of medicine. 2019. 381(21), 1995-2008, DOI: 10.1056/NEJMoa1911303.
7. Rajasekeran H., Lytvyn Y., Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016. 89(3), 524-526, DOI: 10.1016/j.kint.2015.12.038.
8. Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022. 387(12), 1089–1098, doi:
10.1056/NEJMoa2206286.